What are Immix Biopharma Inc's key financial statements?

According to the latest financial statement (Form-10K), Immix Biopharma Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for IMMX?

Immix Biopharma Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Immix Biopharma Inc's revenue broken down by segment or geography?

Immix Biopharma Inc largest revenue segment is United States, at a revenue of 116,706,000 in the most earnings release.For geography, United States is the primary market for Immix Biopharma Inc, at a revenue of 116,706,000.

Is Immix Biopharma Inc profitable?

no, according to the latest financial statements, Immix Biopharma Inc has a net loss of $0

Does Immix Biopharma Inc have any liabilities?

no, Immix Biopharma Inc has liability of 0

How many outstanding shares for Immix Biopharma Inc?

Immix Biopharma Inc has a total outstanding shares of 0

IMMX Financials: Immix Biopharma Inc AI Analysis



Financials

IMMX Financial

Immix Biopharma Inc

$8.01

1.77%

$0.13

At close: Jun 09, 16:00:00 GMT-4

$8.01

Pre-market: Jun 10, 05:46:31 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$7.87

Open

$8.01

Day's Range

$7.8 - $8.23

52 week range

$1.87 - $11.61

Volume

1.3M

Avg.Volume

817.8K

Dividend yield

EPS (TTM)

-0.88

Market Cap

$435.8M

What is IMMX?

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 21 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The firm's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

Features

Markets

News

Breakdown	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025
Revenue	0	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	15	4	5	3	2	2
Research & Development	20	5	5	4	3	1
Operating Expenses	36	10	10	7	6	4
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-34	-10	-10	-7	-6	-4
Income Tax Expense	0	0	0	0	0	0
Net Income	-34	-10	-10	-7	-6	-4
Net Income Growth	70%	150%	150%	0%	50%	-20%
Shares Outstanding (Diluted)	55.36	55.36	40.22	31.92	29.98	29.7
Shares Change (YoY)	86%	86%	36%	9%	4%	27%
EPS (Diluted)	-0.63	-0.18	-0.26	-0.23	-0.22	-0.15
EPS Growth	-11%	19%	63%	-2%	45%	-32%
Free Cash Flow	-32	-9	-11	-6	-5	-1
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	0%	0%	0%	0%	0%
Profit Margin	0%	0%	0%	0%	0%	0%
Free Cash Flow Margin	0%	0%	0%	0%	0%	0%
EBITDA	-36	-10	-10	-7	-6	-4
EBITDA Margin	0%	0%	0%	0%	0%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-36	-10	-10	-7	-6	-4
EBIT Margin	0%	0%	0%	0%	0%	0%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Immix Biopharma Inc (IMMX) Financial

IMMX Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is IMMX?

Immix Biopharma Inc (IMMX) Financial

IMMX Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is IMMX?

IMMX Income

Follow-Up Questions

What are Immix Biopharma Inc's key financial statements?

What are the key financial ratios for IMMX?

How is Immix Biopharma Inc's revenue broken down by segment or geography?

Is Immix Biopharma Inc profitable?

Does Immix Biopharma Inc have any liabilities?

How many outstanding shares for Immix Biopharma Inc?